AstraZeneca's Imfinzi fails in lung cancer trial as a monotherapy to improve OS
AstraZeneca can add another trial to the list of Imfinzi flops.
On Monday, the biopharma announced that its PEARL Phase III trial testing out its blockbuster drug Imfinzi as a monotherapy for lung cancer did not hit its primary endpoint of overall survival.
There are no data yet, however, and the Big Pharma says it will be shared “in due course.”
The PEARL trial, conducted primarily in Asia, looked at Imfinzi as a potential monotherapy for the treatment of patients with Stage IV metastatic non-small cell lung cancer with tumor cells that expressed 25% or more of the protein PD-L1. The other primary endpoint was overall survival in patients identified as low risk of early mortality.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.